- Home
- SXTC vs CBIO Comparison
SXTC vs CBIO Comparison
Compare SXTC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- CBIO
- Stock Information
- Founded
- SXTC 2005
- CBIO 2003
- Country
- SXTC China
- CBIO United States
- Employees
- SXTC N/A
- CBIO N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- CBIO
- Sector
- SXTC Health Care
- CBIO
- Exchange
- SXTC Nasdaq
- CBIO Nasdaq
- Market Cap
- SXTC 164.8M
- CBIO 173.5M
- IPO Year
- SXTC 2019
- CBIO N/A
- Fundamental
- Price
- SXTC $1.90
- CBIO $12.94
- Analyst Decision
- SXTC
- CBIO Strong Buy
- Analyst Count
- SXTC 0
- CBIO 5
- Target Price
- SXTC N/A
- CBIO $25.60
- AVG Volume (30 Days)
- SXTC 860.1K
- CBIO 99.7K
- Earning Date
- SXTC 01-01-0001
- CBIO 07-31-2025
- Dividend Yield
- SXTC N/A
- CBIO N/A
- EPS Growth
- SXTC N/A
- CBIO N/A
- EPS
- SXTC N/A
- CBIO N/A
- Revenue
- SXTC $1,740,907.00
- CBIO N/A
- Revenue This Year
- SXTC N/A
- CBIO N/A
- Revenue Next Year
- SXTC N/A
- CBIO N/A
- P/E Ratio
- SXTC N/A
- CBIO N/A
- Revenue Growth
- SXTC N/A
- CBIO N/A
- 52 Week Low
- SXTC $0.95
- CBIO $10.83
- 52 Week High
- SXTC $7.84
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- SXTC 60.38
- CBIO 47.01
- Support Level
- SXTC $1.33
- CBIO $12.03
- Resistance Level
- SXTC $1.97
- CBIO $13.21
- Average True Range (ATR)
- SXTC 0.21
- CBIO 0.85
- MACD
- SXTC 0.05
- CBIO -0.07
- Stochastic Oscillator
- SXTC 81.91
- CBIO 33.58
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.